Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer.
Barbara Bortot,Maurizio Mongiat,Erica Valencic,Simeone Dal Monego,Danilo Licastro,Matteo Crosera,Gianpiero Adami,Enrico Rampazzo,Giuseppe Ricci,Federico Romano,Giovanni Maria Severini,Stefania Biffi +11 more
TLDR
It is found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug and contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivo.Abstract:
Background Platinum resistance is a major challenge in the management of ovarian cancer Even low levels of acquired resistance at the cellular level lead to impaired response to cisplatin In ovarian cancer intraperitoneal therapy, nanoparticle formulation can improve the cisplatin's pharmacokinetics and safety profile Purpose This work aimed to investigate the chemo-sensitivity of ovarian cancer SKOV3 cells upon short-term (72h) single treatment of cisplatin and cisplatin-loaded biodegradable nanoparticles (Cis-NP) The aim was then to determine the therapeutic properties of Cis-NP in vivo using a SKOV3-luc cells' xenograft model in mice Methods Cell cytotoxicity was assessed after the exposure of the cell culture to cisplatin or Cis-NP The effect of treatments on EMT and CSC-like phenotype was studied by analyzing a panel of markers by flow cytometry Intracellular platinum concentration was determined by inductively coupled plasma mass spectrometry (ICS-MS), and gene expression was evaluated by RNAseq analysis The efficacy of intraperitoneal chemotherapy was evaluated in a SKOV3-luc cells' xenograft model in mice, through a combination of bioluminescence imaging, histological, and immunohistochemical analyses Results We observed in vitro that short-term treatment of cisplatin has a critical role in determining the potential induction of chemoresistance, and a nanotechnology-based drug delivery system can modulate it The RNAseq analysis underlines a protective effect of nanoparticle system according to their ability to down-regulate several genes involved in chemoresistance, cell proliferation, and apoptosis The highest intracellular platinum concentration obtained with Cis-NP treatment significantly improved the efficacy Consistent with in vitro results, we found that Cis-NP treatment in vivo can significantly reduce tumor burden and aggressiveness compared to the free drug Conclusion Nanoparticle-mediated cisplatin delivery may serve as an intracellular depot impacting the cisplatin pharmacodynamic performance at cellular levels These features may contribute to improving the drawbacks of conventional intraperitoneal therapy, and therefore will require further investigations in vivoread more
Citations
More filters
Journal ArticleDOI
Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance.
Yanhua Zhang,Yang Dong,Hao Fu,Hui Huang,Zhihua Wu,Meng Zhao,Xupeng Yang,Qianqian Guo,Yourong Duan,Ying Sun +9 more
TL;DR: NPs-cRGD with ultrasound promoted the apoptosis of resistant ovarian cancer cells by multiple mechanisms, including increased cellular drug accumulation, reversed antiapoptotic effects by siBIRC5, and enhanced ROS levels.
Journal ArticleDOI
Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer
Muhammad Hadi Sultan,Sivakumar Sivagurunathan Moni,Osama Madkhali,Mohammed Ali Bakkari,Saeed Alshahrani,Saad S. Alqahtani,Nabil A. Alhakamy,Syam Mohan,Mohammed Ghazwani,Haitham Bukhary,Yosif Almoshari,Ahmad Salawi,Meshal Fahad M Alshamrani +12 more
TL;DR: In this paper , the authors developed cisplatin-loaded chitosan nanoparticles (CCNP) and mAbCCNP as targeted delivery formulations, which exhibited significant physicochemical properties.
Journal ArticleDOI
Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer
Muhammad Hadi Sultan,Sivakumar Sivagurunathan Moni,Osama Madkhali,Mohammed Ali Bakkari,Saeed Oudah Alshahrani,Saad S. Alqahtani,Nabil A. Alhakamy,Syam Mohan,Mohammed Ghazwani,Haitham Bukhary,Yosif Almoshari,Ahmad Salawi,Meshal Fahad M Alshamrani +12 more
TL;DR: In this article , the authors developed cisplatin-loaded chitosan nanoparticles (CCNP) and mAbCCNP as targeted delivery formulations, which exhibited significant physicochemical properties.
Journal ArticleDOI
Platinum Nanoparticles in Biomedicine: Preparation, Anti-Cancer Activity, and Drug Delivery Vehicles
Atena Abed,Maryam Derakhshan,Merat karimi,Matin Shirazinia,Maryam Mahjoubin-Tehran,M. Homayonfal,Michael R. Hamblin,Seyed Abbas Mirzaei,Hamidreza Soleimanpour,Sadegh Dehghani,F. Farzaneh Dehkordi,Hamed Mirzaei +11 more
TL;DR: The development of PtNPs as an anticancer agent is one of the most valuable approaches for cancer treatment and holds great promise, especially in the area of disease diagnosis, early detection, cellular and deep tissue imaging, drug/gene delivery, as well as multifunctional therapeutics.
Journal ArticleDOI
Potential of curcumin-loaded cubosomes for topical treatment of cervical cancer.
Francesca Damiani Victorelli,Livia Salvati Manni,Stefania Biffi,Barbara Bortot,Hilde Harb Buzzá,Viviane Lutz-Bueno,Stephan Handschin,Giovana Maria Fioramonti Calixto,Sergio Murgia,Marlus Chorilli,Raffaele Mezzenga +10 more
TL;DR: In this article , the authors developed a platform for vaginal administration of lipophilic drugs for cervical cancer treatment and evaluated their potential efficiency using the CAM (chick embryo chorioallantoic membrane) model.
References
More filters
Journal ArticleDOI
Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives.
TL;DR: Several exemplary efforts in nanomedicine for addressing unmet clinical needs are summarized, including nanostructured probes emerging as a new class of medical tool that can simultaneously provide imaging contrast, target tumor cells, and carry a wide range of medicines resulting in better diagnosis and therapeutic precision.
Journal ArticleDOI
Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review
Mudra Binju,Monica Angelica Amaya Padilla,Terence Singomat,Pritinder Kaur,Yohan Suryo Rahmanto,Paul A. Cohen,Yu Yu +6 more
TL;DR: The current understanding of mechanisms that promote recurrence and acquired resistance in epithelial ovarian cancer is reviewed with particular focus on studies that describe differences observed between untreated primary tumors and recurrent tumors, post-first-line chemotherapy.
Journal ArticleDOI
Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation
Nicole S. Anderson,Leslie M. Turner,Sandra Livingston,Ren Chen,Santo V. Nicosia,Patricia A. Kruk +5 more
TL;DR: Ovarian tissue sections were examined to determine the potential relationship between epithelial and stromal Bcl-2 expression in conjunction with the presence of lymphocytes for epithelial ovarian tumor progression and the number of lymphocyte nests dramatically increased with tumor progression.
Journal ArticleDOI
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies
Sara Capolla,Chiara Garrovo,Sonia Zorzet,Andrea Lorenzon,Enrico Rampazzo,Ruben Spretz,Gabriele Pozzato,Luis Nunez,Claudio Tripodo,Paolo Macor,Stefania Biffi +10 more
TL;DR: Evidence is provided that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacokinetic profiles in vivo after systemic administration and increases in vivo imaging of tumor mass compared to non-targeted NPs.
Journal ArticleDOI
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Lyndee L. Scurr,Alexander Guminski,Alexander Guminski,Yoke Eng Chiew,Yoke Eng Chiew,Rosemary L. Balleine,Raghwa Sharma,Ying Lei,Ying Lei,Kylie Pryor,Kylie Pryor,Gerard Wain,Alison Brand,Karen Byth,Catherine Kennedy,Catherine Kennedy,Helen Rizos,Paul R. Harnett,Paul R. Harnett,Anna deFazio,Anna deFazio +20 more
TL;DR: Findings suggest that ANKRD1, a gene not previously associated with ovarian cancer or with response to chemotherapy, is associated with treatment outcome, and decreasing AN KRD1 expression, or function, is a potential strategy to sensitize tumors to platinum-based drugs.